Thursday, August 21, 2014 1:43:52 PM
That particular drug only cured 43% of the animals in the pre clinicals. It's not a good choice based on the animal studies. I'm still amazed they chose it. They must have wanted a drug from a US company. It's the only thing that made sense. The ebola drugs that are furthest ahead have been developed in Canada.
Bottom line, it isn't known whether or not that other drug cured those two or not.
NNVC should simply stick to the flu for now. No need to deviate and waste time. They'll get a much larger sample size to deal with during flu season and the results would be definitive.
In Reply to 'NewMoney'
They were actually trying to convince everyone that they would turn their attention back to ebola for the sake of all mankind but while they were yappin' about it someone else actually stepped up and cured the two medical aid workers.
Done deal. The hot air hasn't even settled yet from NNVC talking about it. But hey, they'll probably be happy to talk about curing something else if they can just dilute the stock a little more.
Just a couple of weeks back NNVC was mankinds only hope to survive this incurable virus. They've been just about to go to tox testing any day for years now, and in a few days some other company stepped up and BAM! cured 'em with a real drug. And it probably didn't even have any magical little nano robots in it.
ROFL!
2 US Ebola patients released from hospital, aid groups say
ATLANTA (AP) — After nearly three weeks of treatment, the two American aid workers who were infected with the deadly Ebola virus in Africa have been discharged from an Atlanta hospital, officials said Thursday.
http://news.msn.com/us/second-american-worker-with-ebola-was-released-from-atlanta-hospital
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM